Skip to content

Patients › General-Health

Sức khỏe xương và bệnh loãng xương

How bone strength affects fractures, fixation and recovery — bone density, fragility fractures, and what helps keep bones strong (lifestyle, supplements and medications).

Updated Nov 2026
Mặt cắt ngang của xương bè thể hiện cấu trúc bên trong dạng tổ ong của nó.
Xương là mô sống; cấu trúc dạng tổ ong bên trong xương trở nên mỏng dần theo tuổi tác và do bệnh loãng xương, làm tăng nguy cơ gãy xương. Kieran Hirpara 4.0

Trang này được dịch bằng máy và chưa được bác sĩ kiểm tra. Bản tiếng Anh là bản chính thức.

Định nghĩa

Hình minh họa về cấu trúc xương xốp thay đổi từ trạng thái bình thường sang mỏng dần và cuối cùng là bị loãng xương.
Bên trong xương: lớp xương xốp có cấu trúc giống “tổ ong” trở nên mỏng dần và mất đi các thanh nâng đỡ khi mật độ xương giảm – đó là hiện tượng mà bệnh loãng xương mô tả. Servier Medical Art, CC BY-SA 3.0

Loãng xương là tình trạng xương của bạn mất dần độ chắc khỏe. Theo thời gian, xương trở nên mỏng và dễ gãy, vì vậy xương có thể bị gãy chỉ sau một cú ngã nhẹ hoặc thậm chí một va chạm nhỏ. Những vị trí gãy xương thường gặp nhất là ở hông, cổ tay và cột sống.

Bạn có thể nghe đến thuật ngữ “gãy xương do xương yếu”. Thuật ngữ này chỉ một chiếc xương bị gãy dễ dàng hơn mức đáng lẽ phải có. Nếu bạn đã từng bị gãy xương kiểu này, đó có thể là dấu hiệu cảnh báo rằng xương của bạn yếu hơn bình thường.

Có một khoảng trống đã được biết đến trong việc chăm sóc ở đây. Nghiên cứu cho thấy những người bị gãy xương theo cách này thường không được kiểm tra loãng xương hoặc không được bắt đầu điều trị [1]. Điều này vẫn xảy ra dù đã có các hướng dẫn điều trị [2]. Điều này quan trọng vì việc điều trị tình trạng xương yếu bên dưới có thể làm giảm khả năng bị gãy xương lần nữa. Các thử nghiệm đã cho thấy điều trị loãng xương sau một lần gãy xương do xương yếu có thể giảm tới 50% nguy cơ gãy xương tiếp theo và giảm tỷ lệ tử vong tới 30% [3].

Xương không phải là thứ cố định, bất biến. Xương là mô sống, liên tục được phân hủy và tái tạo. Loãng xương xuất hiện khi quá trình phân hủy diễn ra nhanh hơn quá trình tái tạo, khiến mật độ xương giảm xuống. Mục tiêu của phòng ngừa là xây dựng bộ xương chắc khỏe nhất có thể, rồi duy trì độ chắc khỏe đó [4]. Mục tiêu của điều trị là ngăn chặn tình trạng mất xương tiếp diễn để lần gãy xương đầu tiên, hoặc một lần gãy xương khác, không bao giờ xảy ra [4].

Một phát hiện đáng biết: một phân tích tổng hợp chín nghiên cứu cho thấy cứ mỗi 1 đơn vị tăng thêm của chỉ số khối cơ thể có liên quan đến nguy cơ loãng xương giảm 9% [5]. Cân nặng cơ thể chỉ là một phần của bức tranh, bên cạnh các yếu tố như tuổi tác, nội tiết tố và sức khỏe tổng thể.

Nếu bạn đã bị gãy xương một cách dễ dàng, hoặc bạn lo lắng về độ chắc khỏe của xương, hãy hỏi về việc kiểm tra mật độ xương. Phát hiện loãng xương sớm giúp bạn có cơ hội tốt nhất để hành động trước khi xảy ra gãy xương.

Phương pháp này có hiệu quả không?

Câu trả lời thẳng thắn là việc điều trị hiệu quả nhất khi được bắt đầu sớm, và cách thực hiện điều đó vẫn còn chỗ cần cải thiện. Nghiên cứu cho thấy những người bị gãy xương cổ tay được kiểm tra loãng xương thường xuyên hơn nhiều khi họ tham gia một chương trình chuyên biệt so với khi được chăm sóc thông thường: 92% so với 23% [6]. Các nghiên cứu khác cho thấy những người bị gãy xương hông hoặc xương cột sống thường hoàn toàn không được bắt đầu điều trị tăng cường sức mạnh xương, mặc dù các hướng dẫn khuyến nghị điều đó [7] [2]. Đó là lý do tại sao việc hỏi về kiểm tra mật độ xương sau bất kỳ lần gãy xương dễ dàng nào lại quan trọng đến vậy.

Khi đã được chẩn đoán loãng xương, có bằng chứng cho thấy điều trị có thể giúp xương lành và giảm khả năng bị gãy xương lần nữa. Trong một thử nghiệm, những người bị gãy xương cổ tay được tiêm một loại hormone kích thích tạo xương đã lành xương sau 7.8 tuần, so với 12.6 tuần ở những người không được điều trị [8]. Tập luyện cũng có vai trò. Người bị loãng xương nên tập các bài tập kháng lực và bài tập chịu tác động để tối đa hóa độ chắc khỏe của xương, cùng với các hoạt động cải thiện sức mạnh và thăng bằng để giảm nguy cơ té ngã, và các bài tập duỗi cột sống để cải thiện tư thế [9].

Một số nghiên cứu mới hơn chưa có kết luận rõ ràng. Các công cụ học máy dự đoán loãng xương từ phim chụp hoặc xét nghiệm máu cho thấy triển vọng, nhưng các tổng quan nhận thấy chúng có nguy cơ sai lệch cao và chưa được kiểm chứng đầy đủ tại các phòng khám [10]. Và một phân tích cho thấy một loại thuốc điều trị tiểu đường từng được cho là có tác dụng bảo vệ xương đã không làm giảm gãy xương cổ tay và cánh tay sau khi tính đến các yếu tố sức khỏe khác [11]. Nếu bạn bị loãng xương và bị gãy xương, việc điều trị bản thân chỗ xương gãy sẽ hiệu quả hơn khi tình trạng xương yếu bên dưới được điều trị cùng lúc [12].

Những rủi ro là gì?

Rủi ro chính của việc không điều trị loãng xương là gãy xương. Nếu bạn đã từng bị một lần gãy xương do xương yếu, xương của bạn dễ bị gãy lần nữa hơn, đặc biệt nếu tình trạng xương yếu bên dưới không được điều trị [7] [2]. Nghiên cứu cho thấy điều trị được bắt đầu sau lần gãy xương đầu tiên làm giảm khả năng bị gãy xương lần nữa, và đây là lý do mạnh mẽ nhất để hành động sớm [3].

Cũng có những rủi ro xung quanh chính thời điểm bị gãy xương. Một nghiên cứu cho thấy những người bị loãng xương gặp nhiều biến chứng nội khoa hơn trong 90 ngày đầu sau phẫu thuật so với những người không bị loãng xương [13]. Xương gãy cũng có thể lành theo cách khác nhau tùy thuộc vào độ chắc khỏe của xương. Trong một nghiên cứu về gãy xương cổ tay di lệch, mức cải thiện biến dạng là 12.5 ở những người bị loãng xương, chưa bằng một nửa mức 25.6 ở những người có chất lượng xương tốt [14]. Một nghiên cứu khác cho thấy riêng tình trạng xương yếu ở người cao tuổi không ngăn cản xương gãy liền lại [15].

Nếu bạn bị loãng xương và cần phẫu thuật khớp hoặc gân, bức tranh rõ ràng hơn. Các tổng quan về phẫu thuật nội soi khâu chóp xoay không tìm thấy mối liên hệ giữa mật độ xương thấp hơn và kết quả sau 2 năm, và tỷ lệ biến chứng thấp [16] [17]. Không nên xem loãng xương là lý do để loại trừ phẫu thuật này [17].

Một số phương pháp điều trị có những điểm chưa chắc chắn riêng. Calcitonin dạng xịt mũi có hiệu quả kém hơn các loại thuốc điều trị xương khác trong việc làm chắc xương và giảm nguy cơ gãy xương [18]. Bằng chứng về châm cứu và các sản phẩm y học cổ truyền Trung Quốc vẫn còn ở giai đoạn đầu, và cần được kiểm chứng thêm [19] [20]. Đối với tiêm hormone tuyến cận giáp, thời điểm dùng thuốc tốt nhất vẫn đang được nghiên cứu trong các thử nghiệm [21].

Khoảng trống thực sự nằm ở việc theo dõi đến cùng. Các nghiên cứu cho thấy nhiều người bị gãy xương hông, cột sống hoặc cổ tay hoàn toàn không bao giờ được bắt đầu điều trị tăng cường sức mạnh xương [7] [2] [22]. Hỏi về việc điều trị sau bất kỳ lần gãy xương dễ dàng nào là bước an toàn nhất bạn có thể thực hiện.

Liệu phương pháp này có phù hợp với bạn không?

Điều trị tăng cường sức mạnh xương là điều đáng cân nhắc nếu bạn đã được cho biết xương của mình yếu, hoặc nếu bạn đã bị gãy xương dễ dàng hơn mức đáng lẽ phải có. Mục tiêu là ngăn chặn tình trạng mất xương tiếp diễn trước khi xảy ra lần gãy xương đầu tiên, hoặc một lần gãy xương khác [4]. Điều trị sau một lần gãy xương do xương yếu cũng quan trọng. Việc này có thể làm giảm khả năng bị gãy xương lần nữa và giảm tỷ lệ tử vong [3]. Nhưng nghiên cứu cho thấy nhiều người bị gãy xương hông, cột sống hoặc cổ tay hoàn toàn không bao giờ được bắt đầu điều trị [7] [2]. Vì vậy, nếu bạn đã từng bị gãy xương dễ dàng, việc hỏi bác sĩ về kiểm tra mật độ xương và liệu điều trị có giúp ích cho bạn hay không là hoàn toàn hợp lý.

Một số người ít có khả năng cần điều trị hơn. Nếu xương của bạn vẫn còn chắc khỏe, trọng tâm là giữ cho xương luôn như vậy: xây dựng bộ xương chắc khỏe nhất có thể, rồi duy trì độ chắc khỏe đó [4]. Tập luyện đóng một vai trò ở đây. Người bị loãng xương nên tập các bài tập kháng lực và bài tập chịu tác động để tối đa hóa độ chắc khỏe của xương [9]. Bác sĩ có thể giúp bạn xác định điều gì là an toàn cho bạn.

Điều trị không phải là một giải pháp áp dụng chung cho tất cả mọi người. Có nhiều loại thuốc điều trị xương khác nhau, và loại phù hợp phụ thuộc vào sức khỏe của bạn, tiền sử gãy xương và những ưu tiên riêng của bạn. Đây nên là quyết định chung giữa bạn và bác sĩ. Hãy hỏi xem mỗi lựa chọn bao gồm những gì, các tác dụng phụ có thể có là gì (được đề cập trong phần rủi ro ở trên), và bạn sẽ cần duy trì điều trị trong bao lâu. Nếu có điều gì chưa rõ, hãy tiếp tục hỏi cho đến khi bạn cảm thấy tự tin với kế hoạch.

Tóm lại

Điều trị loãng xương là điều đáng cân nhắc nếu xương của bạn yếu hoặc bạn đã bị gãy xương một cách dễ dàng. Mục tiêu là ngăn chặn tình trạng mất xương tiếp diễn trước khi xảy ra gãy xương, hoặc một lần gãy xương khác [4]. Hành động sớm rất quan trọng, vì điều trị sau một lần gãy xương do xương yếu có thể làm giảm khả năng bị gãy xương lần nữa và giảm tỷ lệ tử vong [3]. Lưu ý quan trọng nhất là việc theo dõi đến cùng: nhiều người bị gãy xương hông, cột sống hoặc cổ tay hoàn toàn không bao giờ được kiểm tra hay điều trị [7] [2]. Vì vậy, nếu bạn đã từng bị gãy xương dễ dàng, hãy đề nghị kiểm tra mật độ xương và tiếp tục hỏi cho đến khi bạn có một kế hoạch.

Tài liệu tham khảo

[1] The osteoporosis care gap in Canada. BMC Musculoskeletal Disorders. 2004. DOI: 10.1186/1471-2474-5-11

[2] A Missed Opportunity? Osteoporosis Treatment Following Femoral Neck Fractures: Reducing the Risk of Secondary Hip Fracture. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2025.07.028

[3] Medical management of osteoporosis and the doctor's' role. Injury. 2016. DOI: 10.1016/s0020-1383(16)30014-6

[4] BONE HEALTH AND OSTEOPOROSIS. Clinics in Sports Medicine. 2000. DOI: 10.1016/s0278-5919(05)70201-5

[5] The association between body mass index and osteoporosis, with consideration of sex differences: a systematic review and dose-response meta-analysis. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09675-3

[6] Wristwatch—distal radial fracture as a marker for osteoporosis investigation:. Journal of Hand Therapy. 2004. DOI: 10.1197/j.jht.2004.04.001

[7] The Management of Pelvic and Vertebral Fragility Fractures: An Unmet Care Need. Journal of Bone and Joint Surgery. 2026. DOI: 10.2106/jbjs.26.00966

[8] Use of teriparatide in osteoporotic fracture patients. Injury. 2016. DOI: 10.1016/s0020-1383(16)30009-2

[9] Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. British Journal of Sports Medicine. 2022. DOI: 10.1136/bjsports-2021-104634

[10] Risk prediction models for postmenopausal osteoporosis: a systematic review and meta-analysis study. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-025-09385-2

[11] Glucagon-like peptide-1 receptor agonist use for type 2 diabetes and risk of upper extremity fragility fracture. Injury. 2026. DOI: 10.1016/j.injury.2026.113456

[12] Continuity and volume of bone cement and anti osteoporosis treatment were guarantee of good clinical outcomes for percutaneous vertebroplasty: a multicenter study. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-024-08153-y

[13] Impact of osteoporosis on post-operative outcomes following rotator cuff repair. JSES Reviews, Reports, and Techniques. 2026. DOI: 10.1016/j.xrrt.2026.100723

[14] Osteoporosis and colles' fractures in the elderly. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand. 1987. DOI: 10.1016/0266-7681(87)90058-1

[15] A89 Osteoporosis is not a risk factor for the development of nonunion: a cohort nested case-control study. Injury. 2011. DOI: 10.1016/s0020-1383(11)70106-1

[16] No difference in 2-year outcomes of arthroscopic rotator cuff repair in patients with osteoporosis. Journal of Shoulder and Elbow Surgery. 2025. DOI: 10.1016/j.jse.2025.02.011

[17] Osteoporosis is a risk factor for complications and reoperations at 1 and 3 years after arthroscopic rotator cuff repair. JSES International. 2026. DOI: 10.1016/j.jseint.2026.101678

[18] Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management. JBJS Reviews. 2026. DOI: 10.2106/jbjs.rvw.26.00021

[19] Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05513-9

[20] Natural traditional Chinese medicine products: emerging therapeutic targets for the treatment of osteoporosis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05879-w

[21] Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06083-6

[22] Incidence of Anti-osteoporosis Diagnosis and Treatment After Distal Radius Fractures. HAND. 2016. DOI: 10.1177/1558944716660555dj


Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • Fragility fractures represent a major and growing global health concern [15].
  • Prevention of osteoporosis is accomplished by maximizing peak bone density and maintaining that bone density [6].
  • The goal of osteoporosis treatment is to stop further bone loss to prevent a fracture or any subsequent fragility fractures [6].
  • There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada [12].
  • Treatment of the underlying osteoporosis to prevent secondary fractures is rarely initiated following pelvic and vertebral fragility fractures [7].
  • Treatments for pelvic and vertebral fragility fractures vary widely and are not always evidence-based [7].
  • Wider recognition of common risk factors of osteoporosis and the expansion of screening protocols are necessary to ensure that osteoporosis is properly diagnosed and treated in patients receiving lumbar fusion [3].
  • Findings from over one million cases support early, coordinated post-fracture osteoporosis treatment following an initial fragility fracture [4].
  • The observational design of the study on recurrent hip fracture risk precludes causal inference [4].
  • Each 1-unit increase in body mass index was associated with a 9% reduction in osteoporosis risk based on a dose-response analysis of nine studies [8].
  • A bone density based aging model approach may facilitate and support the development of precision medicine strategies in osteoporosis prevention and management [1].
  • A nomogram with an online dynamic calculator could facilitate the early prediction, diagnosis, and treatment of osteoporosis, contributing to the bone health of the elderly population and promoting the development of public health [20].
  • Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patients following rotator cuff repair [22].
  • Overall rates of complication after arthroscopic rotator cuff repair were low, and osteoporosis should not be considered a contraindication to the procedure [33].
  • Patients with distal radial fractures in elderly women should be screened for osteoporosis [23].
  • The ability of monocytes to fuse declines significantly in patients with osteoporosis [55].
  • Intranasal salmon calcitonin is less effective than bisphosphonates and modern anabolic agents for increasing bone mineral density and reducing fracture risk [11].
  • The use of intranasal salmon calcitonin is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference [11].
  • Sequential anabolic-to-anti-resorptive therapy may inform treatment guidelines for high-risk postmenopausal populations [9].
  • Current online health information on osteoporosis often fails to meet basic standards of evidence-based health information, highlighting the urgent need to improve quality to support informed decision-making [5].
  • Investigators must select an osteoporotic fracture model that best reflects the clinical problem being studied and the underlying pathophysiology of the osteoporosis in the target patient group [2].
  • There is no perfect model for osteoporosis, but a variety of models are appropriate for answering specific questions [10].

How It Works

Pathophysiology and Mechanisms

  • Hypothalamic-pituitary disconnection leads to osteoporosis with a reduction in both trabecular and cortical bone caused by a low bone turnover situation, with reduced osteoblast and osteoclast activity [29].
  • Evidence of early changes in bone geometry and increased bone turnover could be used to detect osteoporosis before estrogen deficiency has adversely affected bone strength [27].
  • MiR-137 promotes TLR4/NF-κB pathway activity through targeting KDM4A, which inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis [37].
  • The gut microbiota–metabolite–bone network may be involved in the skeletal effects of leptin, providing mechanistic insights for osteoporosis management [36].
  • Macrophage polarization-related genes have potential causal roles in osteoporosis, though these findings are exploratory and require validation in bone marrow-specific and functional studies [35].

Risk Factors and Screening

  • Each 1-unit increase in BMI was associated with a 9% reduction in osteoporosis risk based on a dose-response analysis of nine studies [8].
  • Postmenopausal women with distal radius fractures have diminished bone mass, which might make a bone more likely to break [45].
  • Machine learning application to hand radiographs represents a possible step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis/osteopenia [19].
  • A nomogram with an online dynamic calculator developed based on NHANES data could facilitate the early prediction, diagnosis, and treatment of osteoporosis [20].
  • A bone density-based aging model may facilitate the development of precision medicine strategies in osteoporosis prevention and management [1].
  • Current online health information on osteoporosis often fails to meet basic standards of evidence-based health information, highlighting the need to improve quality to support informed decision-making [5].

Treatment and Management

  • Prevention of osteoporosis can be accomplished by maximizing peak bone density and maintaining that bone density, although the goal of treatment is to stop further bone loss to prevent a fracture or any subsequent fragility fractures [6].
  • Randomized controlled trials have demonstrated that treatment of osteoporosis in patients with fragility fractures can reduce the risk of subsequent fractures by up to 50% and mortality rates by up to 30% [18].
  • Intranasal salmon calcitonin is less effective than bisphosphonates and modern anabolic agents for increasing BMD and reducing fracture risk, and its use is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference [11].
  • The current evidence suggests that the efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention [16].
  • Late osteoporosis treatment was associated with no significant further decline in periprosthetic BMD but did not reverse severe proximal bone loss [28].
  • Treatment of the underlying osteoporosis to prevent secondary fractures is rarely initiated, and treatments for pelvic and vertebral fragility fractures vary widely and are not always evidence-based [7].
  • These findings support early, coordinated post-fracture osteoporosis treatment, although the observational design precludes causal inference [4].
  • A program for secondary osteoporotic fracture prevention is needed following distal radius fractures [30].
  • Natural traditional Chinese medicine products provide a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management [24].
  • Findings from studies on long-term hospitalized patients with muscular dystrophy may help inform strategies for osteoporotic treatment and nutritional care in this patient population [17].

Fracture Healing and Repair

  • The effect of ovariectomy on fracture repair was to delay healing as evidenced by histological and radiological analysis, and the deleterious effect might be more related to change of structure than to loss of BMD [41].
  • In humans, de novo use of bisphosphonate therapy after fracture does not appear to have a significant effect on fracture healing [46].
  • Although bone quality may be diminished in the elderly, this does not influence the occurrence of nonunion [47].
  • Prior bisphosphonate treatment affects the mineralization pattern of the tissue repair consistently with a reduction in bone turnover, but does not abolish the repair process [26].
  • There is some promising experimental and clinical evidence for possible enhancement of the bone repair process via administration of systemic agents [39].
  • Fracture healing in SAMP6 mice is not detrimentally affected by impairment of bone marrow stem cell osteogenesis, suggesting that bone marrow-mediated repair processes are dispensable for normal bone healing in this senile osteoporotic fracture model [44].
  • Cracks in bone following bisphosphonate treatment were shorter than in control or ovariectomized groups, which may explain why increased damage levels following bisphosphonate treatment have not led to increased fractures [40].
  • Bone histomorphometry revealed that bone architecture in the treatment group using a calcitonin release system was improved and results were not different from those observed after calcitonin injection [31].

Clinical Outcomes and Assessment

  • There was no relationship between decreased bone mineral density and 2-year clinical outcomes following arthroscopic rotator cuff repair in patients with osteoporosis [21].
  • Multiscale biomechanical assessment approaches have potential applications in fracture risk assessment, the design of patient-specific implants, and research into the mechanisms of bone metabolic diseases [38].
  • Investigators must select an animal model that best reflects the clinical problem being studied and the underlying pathophysiology of the osteoporosis in the target patient group [2].

What the Evidence Shows

Epidemiology and Risk Factors

  • Fragility fractures are a major and growing global health concern [15].
  • Each 1-unit increase in body mass index is associated with a 9% reduction in osteoporosis risk [8].
  • Type 2 diabetes shows significant associations with femoral neck and total body bone mineral density, while HbA1c shows significant associations with heel bone mineral density [56].
  • Osteoporosis is present in long-term hospitalized patients with muscular dystrophy, informing strategies for osteoporotic treatment and nutritional care in this population [17].

Diagnosis and Screening

  • There is a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada [12].
  • Osteoporosis screening gaps exist among patients undergoing lumbar fusion surgery, necessitating wider recognition of risk factors and expanded screening protocols [3].
  • Patients with distal radial fractures should be screened for osteoporosis [23].
  • Intervention programs for distal radius fractures increased the rate of osteoporosis investigation from 26.6% in controls to 87.5% in intervention participants [32].
  • Intervention subjects for distal radial fractures were investigated for osteoporosis at a rate of 92%, compared to 23% in the usual-care group [43].
  • Machine learning models applied to hand radiographs represent a step toward more accessible, cost-effective, and automated diagnosis of osteoporosis and osteopenia [19].
  • A fracture risk prediction model based on routine blood test markers was successfully developed and validated for patients newly diagnosed with osteoporosis [52].
  • Current machine learning-based prediction models for postmenopausal osteoporosis without fractures demonstrate good discriminative ability but are characterized by a high risk of bias, lack of calibration performance evaluation, and insufficient validation of clinical utility [58].
  • Online health information on osteoporosis often fails to meet basic standards of evidence-based health information [5].

Treatment and Management

  • Prevention of osteoporosis can be accomplished by maximizing peak bone density and maintaining that bone density [6].
  • Treatment of osteoporosis in patients with fragility fractures can reduce the risk of subsequent fractures by up to 50% and mortality rates by up to 30% [18].
  • Early, coordinated post-fracture osteoporosis treatment is supported by findings from over one million cases, though the observational design precludes causal inference [4].
  • Treatment of the underlying osteoporosis to prevent secondary fractures is rarely initiated in patients with pelvic and vertebral fragility fractures [7].
  • Patients receiving parathyroid hormone (1–84) injections experienced accelerated radiographic and clinical fracture healing at 7.8 weeks compared to 12.6 weeks in untreated patients [48].
  • Late osteoporosis treatment was associated with no significant further decline in periprosthetic bone mineral density but did not reverse severe proximal bone loss after cementless total hip arthroplasty [28].
  • Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for percutaneous vertebroplasty [50].
  • Injected bone cement greater than 5.5 ml might be a guarantee of good clinical outcomes for percutaneous vertebroplasty [50].
  • Prior bisphosphonate treatment affects the mineralization pattern of tissue repair following vertebral fragility fracture, consistent with reduced bone turnover, but does not abolish the repair process [26].
  • The efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention [16].
  • Key recommendations for people with osteoporosis include undertaking resistance and impact exercise to maximize bone strength [34].
  • Key recommendations for people with osteoporosis include activities to improve strength and balance to reduce falls [34].
  • Key recommendations for people with osteoporosis include spinal extension exercise to improve posture and potentially reduce the risk of falls and vertebral fractures [34].

Surgical Outcomes and Complications

  • There is no relationship between decreased bone mineral density and 2-year clinical outcomes following arthroscopic rotator cuff repair [21].
  • Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period following rotator cuff repair than nonosteoporotic patients [22].
  • In severely displaced distal radial fractures, the final improvement in bony deformity was significantly less in patients with osteoporosis compared to those without [53].
  • The initial deformity in severely displaced distal radial fractures was not influenced by osteoporosis [53].

Research Models

  • Hypothalamic-pituitary disconnection leads to low turnover osteoporosis in sheep after 12 months, characterized by a reduction in both trabecular and cortical bone with reduced osteoblast and osteoclast activity [29].

Practical Considerations

Screening and Diagnosis

  • A bone density-based aging model approach may facilitate the development of precision medicine strategies in osteoporosis prevention and management [1].
  • Machine learning application to hand radiographs represents a possible step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis or osteopenia [19].
  • In a study of wristwatch interventions, seven of the eight remaining intervention participants were investigated for osteoporosis (87.5%), compared to four of the remaining 15 control subjects (26.6%) [32].
  • Patients with hand fragility fractures represent a high-risk cohort that is currently underserved by osteoporosis screening pathways [42].
  • A cortical bone thickness average below 4.5 mm should prompt DXA referral to improve preoperative bone health assessment without added cost or radiation [49].

Treatment and Management

  • Intranasal salmon calcitonin is less effective than bisphosphonates and modern anabolic agents for increasing bone mineral density and reducing fracture risk, and its use is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference [11].
  • Findings from a prospective observational study highlight opportunities for systematic primary and secondary fracture prevention and structured medication review prior to femoral fracture [25].
  • Findings from a retrospective cross-sectional study may help inform strategies for osteoporotic treatment and nutritional care in long-term hospitalized patients with muscular dystrophy [17].

Surgical Considerations

  • Despite previous literature showing the negative effect of osteoporosis on rotator cuff healing, data showed no relationship between decreased bone mineral density and 2-year clinical outcomes following arthroscopic rotator cuff repair [21].

Lifestyle and Prevention

  • Key recommendations for people with osteoporosis include undertaking resistance and impact exercise to maximise bone strength [34].
  • Key recommendations for people with osteoporosis include spinal extension exercise to improve posture and potentially reduce risk of falls and vertebral fractures [34].

Research Models

Key Evidence

  • [L3] This approach may facilitate and support the development of precision medicine strategies in osteoporosis prevention and management. [1] (10.1186/s12891-025-09298-0)
  • [L5] Investigators must select a model that best reflects the clinical problem being studied, and the underlying pathophysiology of the osteoporosis in the target patient group. [2] (10.1016/s0020-1383(16)30004-3)
  • [Paper] Wider recognition of common risk factors of osteoporosis and the expansion of screening protocols are necessary to ensure that osteoporosis is properly diagnosed and treated in patients receiving lumbar fusion. [3] (10.5435/jaaos-d-26-00335)
  • [Paper] These findings support early, coordinated post-fracture osteoporosis treatment; the observational design precludes causal inference. [4] (10.1016/j.injury.2026.113865)
  • [Paper] Current OHI on osteoporosis often fails to meet basic standards of EBHI, highlighting the urgent need to improve the quality to support informed decision-making. [5] (10.1186/s12891-026-09711-2)
  • [Paper] Prevention of osteoporosis can be accomplished by maximizing peak bone density and maintaining that bone density, although the goal of treatment is to stop further bone loss to prevent a fracture or any subsequent fragility fractures. [6] (10.1016/s0278-5919(05)70201-5)
  • [L5] The treatments vary widely and are not always evidence-based and, unfortunately, treatment of the underlying osteoporosis to prevent secondary fractures is rarely initiated. [7] (10.2106/jbjs.26.00966)
  • [L1] Based on our dose-response analysis of nine studies, each 1-unit increase in BMI was associated with a 9% reduction in osteoporosis risk. [8] (10.1186/s12891-026-09675-3)
  • [L1] This sequential anabolic-to-anti-resorptive therapy may inform treatment guidelines for high-risk postmenopausal populations. [9] (10.1186/s13018-025-06040-3)
  • [Paper] However, there is no perfect model for osteoporosis, but a variety of models appropriate for answering specific questions. [10] (10.1016/s0020-1383(16)30002-x)
  • [Paper] IN-CAL is less effective than bisphosphonates and modern anabolic agents for increasing BMD and reducing fracture risk; accordingly, its use is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference. [11] (10.2106/jbjs.rvw.26.00021)
  • [L4] There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada. [12] (10.1186/1471-2474-5-11)
  • [Paper] Fragility fractures are a major and growing global health concern. [15] (10.1016/j.injury.2026.113902)
  • [L1] The current evidence suggests that the efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention. [16] (10.1186/s13018-025-05513-9)
  • [L4] These findings may help inform strategies for osteoporotic treatment and nutritional care in this patient population. [17] (10.1186/s12891-026-10045-2)
  • [Paper] Randomized controlled trials have demonstrated that treatment of osteoporosis in patients with fragility fractures can reduce the risk of subsequent fractures by up to 50% and mortality rates by up to 30%. [18] (10.1016/s0020-1383(16)30014-6)
  • [L2] The findings represent a possible step toward more accessible, cost-effective, automated diagnosis and therefore earlier treatment of osteoporosis/osteopenia. [19] (10.1016/j.jhsa.2024.09.008)
  • [L3] Ultimately, this tool could facilitate the early prediction, diagnosis, and treatment of osteoporosis, thus contributing to the bone health of the elderly population and promoting the development of public health. [20] (10.1186/s12891-026-09920-9)
  • [L3] Despite previous literature showing the negative effect of osteoporosis on rotator cuff healing, our data showed no relationship between decreased bone mineral density and 2-year clinical outcomes following RCR. [21] (10.1016/j.jse.2025.02.011)
  • [L3] In addition, patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patient. [22] (10.1016/j.xrrt.2026.100723)
  • [L4] It is the authors' opinion that such patients should be screened for osteoporosis. [23] (10.1016/j.jhsb.2004.05.002)
  • [L4] This paper summarises recent research progress on natural TCM products in preventing and treating osteoporosis and provides a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management. [24] (10.1186/s13018-025-05879-w)
  • [L3] These findings highlight important opportunities for systematic primary and secondary fracture prevention and structured medication review. [25] (10.1007/s00402-026-06401-5)
  • [L4] Prior bisphosphonate treatment affects the mineralization pattern of the tissue repair consistently with a reduction in bone turnover as found in post-menopausal osteoporotic women, but does not abolish the repair process. [26] (10.1002/jor.22026)
  • [Paper] Therefore, evidence of early changes in bone geometry and increased bone turnover could be used to detect osteoporosis before estrogen deficiency has adversely affected bone strength. [27] (10.1002/jor.20961)
  • [Paper] Late osteoporosis treatment was associated with no significant further decline in periprosthetic BMD but did not reverse severe proximal bone loss. [28] (10.1007/s00264-026-07068-8)
  • [Paper] HPD leads after 12 month to osteoporosis with a reduction in both trabecular and cortical bone caused by a low bone turnover situation, with reduced osteoblast and osteoclast activity, as compared to controls (OVX). [29] (10.1002/jor.22066)
  • [L4] The results of our study evidenced the need of a program for secondary osteoporotic fracture prevention; this program has now been developed and is active at our institution. [30] (10.1177/1558944716660555dj)
  • [Paper] Bone histomorphometry revealed that bone architecture in the treatment group was improved and results were not different from those observed after calcitonin injection. [31] (10.1016/s0736-0266(01)00074-7)
  • [L1] Seven of the eight remaining intervention participants were investigated for osteoporosis (87.5%), compared to four of the remaining 15 control subjects (26.6%). [32] (10.1197/j.jht.2003.10.030)
  • [L3] Overall rates of complication were low and osteoporosis should not be considered a contraindication to arthroscopic RCR. [33] (10.1016/j.jseint.2026.101678)
  • [L5] Key recommendations are that people with osteoporosis should undertake (1) resistance and impact exercise to maximise bone strength; (2) activities to improve strength and balance to reduce falls; (3) spinal extension exercise to improve posture and potentially reduce risk of falls and vertebral fractures. [34] (10.1136/bjsports-2021-104634)
  • [Paper] These findings are exploratory and hypothesis-generating and require validation in bone marrow-specific and functional studies. [35] (10.1186/s13018-026-06905-1)
  • [Paper] These findings suggest that the gut microbiota–metabolite–bone network may be involved in the skeletal effects of leptin, providing novel mechanistic insights and potential therapeutic strategies for osteoporosis management. [36] (10.1186/s12891-026-09950-3)
  • [Paper] This mechanism inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis. [37] (10.1186/s13018-023-03918-y)
  • [L5] It explores the potential applications of these multiscale approaches in fracture risk assessment, the design of patient-specific implants, and research into the mechanisms of bone metabolic diseases. [38] (10.1016/j.injury.2026.113659)
  • [Paper] There is some promising experimental and clinical evidence for possible enhancement of the bone repair process via administration of systemic agents. [39] (10.1016/s0020-1383(16)30003-1)
  • [Paper] However, these cracks were shorter than in control or OVX groups which may provide one explanation as to why increased damage levels following bisphosphonate treatment have not lead to increased fractures. [40] (10.1002/jor.21229)
  • [Paper] The effect of OVX on fracture repair was to delay healing as evidenced by histological and radiological analysis, and the evidence suggests that the deleterious effect might be more related to change of structure than to loss of BMD. [41] (10.1002/jor.20505)
  • [L3] Patients with hand fragility fractures represent a high-risk cohort that is currently underserved by osteoporosis screening pathways. [42] (10.1016/j.injury.2026.113261)
  • [L2] Results indicate that 92% of the intervention subjects were investigated for osteoporosis, compared with the usual-care group, in which only 23% were investigated. [43] (10.1197/j.jht.2004.04.001)
  • [Paper] Fracture healing in SAMP6 mice is not detrimentally affected by impairment of BMSC osteogenesis, suggesting that bone marrow-mediated repair processes are dispensable for normal bone healing in this senile osteoporotic fracture model. [44] (10.1002/jor.21041)
  • [L4] They also have diminished bone mass, which might make a bone more likely to break. [45] (10.1016/0363-5023(88)90227-4)
  • [L4] In humans, de novo use of bisphosphonate therapy after fracture does not appear to have a significant effect on fracture healing. [46] (10.1016/s0020-1383(16)30015-8)
  • [L3] Although bone quality may be diminished in the elderly, this does not influence the occurrence of nonunion. [47] (10.1016/s0020-1383(11)70106-1)
  • [Paper] Patients who received the PTH (1–84) injections accelerated radiographic and clinical fracture healing (7.8 weeks) when compared to patients who received no treatment (12.6 weeks). [48] (10.1016/s0020-1383(16)30009-2)
  • [L4] A CBTavg below 4.5 mm should prompt DXA referral, improving preoperative bone health assessment without added cost or radiation. [49] (10.1177/17585732261491314)
  • [L3] Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for PVP, and injected bone cement >5.5 ml might be a guarantee. [50] (10.1186/s12891-024-08153-y)
  • [L3] We successfully developed and validated a fracture risk prediction model for patients newly diagnosed with osteoporosis. [52] (10.1186/s12891-026-09768-z)
  • [L3] In severely displaced fractures, the initial deformity was not influenced by osteoporosis, but the final improvement in bony deformity was significantly less in patients with osteoporosis. [53] (10.1016/0266-7681(87)90058-1)
  • [L4] It was clearly demonstrated that the ability of monocytes to fuse declines significantly in patients with osteoporosis. [55] (10.1002/jor.1100180215)
  • [Paper] The results show varying associations across different BMD sites (femoral neck, lumbar spine, heel, total body) and methods (IVW, MR-Egger, Weighted median), with some significant associations found for T2D on femoral neck and total body BMD, and HbA1c on heel BMD. [56] (10.1186/s12891-024-07430-0)
  • [L1] Current machine learning-based prediction models for postmenopausal osteoporosis without fractures demonstrate good discriminative ability but are generally characterized by a high risk of bias, a notable lack of calibration performance evaluation, and insufficient validation of clinical utility. [58] (10.1186/s12891-025-09385-2)

References

[1] Unveiling risk factors and predicting osteoporosis through bone density based aging model: a community-based cohort in Guangdong, China. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-09298-0

[2] Main differences in osteoporotic fracture models: which should I use?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30004-3

[3] Osteoporosis Screening Gaps Among Patients Undergoing Lumbar Fusion Surgery. Journal of the American Academy of Orthopaedic Surgeons. 2026. DOI: 10.5435/jaaos-d-26-00335

[4] Osteoporosis Treatment Gaps and Risk of Recurrent Hip Fracture Following Initial Fragility Fracture: Insights from Over One Million Cases. Injury. 2026. DOI: 10.1016/j.injury.2026.113865

[5] Mapping the quality of information on osteoporosis: a cross-sectional analysis of online health information. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09711-2

[6] BONE HEALTH AND OSTEOPOROSIS. Clinics in Sports Medicine. 2000. DOI: 10.1016/s0278-5919(05)70201-5

[7] The Management of Pelvic and Vertebral Fragility Fractures: An Unmet Care Need. Journal of Bone and Joint Surgery. 2026. DOI: 10.2106/jbjs.26.00966

[8] The association between body mass index and osteoporosis, with consideration of sex differences: a systematic review and dose-response meta-analysis. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09675-3

[9] Effectiveness of anabolic and anti-resorptive agents for preventing postmenopausal osteoporosis fractures: a systematic review and network meta-analysis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06040-3

[10] Can we induce osteoporosis in animals comparable to the human situation?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30002-x

[11] Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management. JBJS Reviews. 2026. DOI: 10.2106/jbjs.rvw.26.00021

[12] The osteoporosis care gap in Canada. BMC Musculoskeletal Disorders. 2004. DOI: 10.1186/1471-2474-5-11

[15] Fragility fractures: an increasing issue in the ageing population worldwide. Injury. 2026. DOI: 10.1016/j.injury.2026.113902

[16] Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05513-9

[17] Osteoporosis in long-term hospitalized patients with muscular dystrophy: a retrospective cross-sectional study. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-10045-2

[18] Medical management of osteoporosis and the surgeons' role. Injury. 2016. DOI: 10.1016/s0020-1383(16)30014-6

[19] Application of Machine Learning to Osteoporosis and Osteopenia Screening Using Hand Radiographs. The Journal of Hand Surgery. 2025. DOI: 10.1016/j.jhsa.2024.09.008

[20] A nomogram with online dynamic calculator for predicting osteoporosis: development and validation based on NHANES. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09920-9

[21] No difference in 2-year outcomes of arthroscopic rotator cuff repair in patients with osteoporosis. Journal of Shoulder and Elbow Surgery. 2025. DOI: 10.1016/j.jse.2025.02.011

[22] Impact of osteoporosis on post-operative outcomes following rotator cuff repair. JSES Reviews, Reports, and Techniques. 2026. DOI: 10.1016/j.xrrt.2026.100723

[23] The Distal Radial Fracture in Elderly Women and the Bone Mineral Density of the Lumbar Spine and Hip. Journal of Hand Surgery. 2004. DOI: 10.1016/j.jhsb.2004.05.002

[24] Natural traditional Chinese medicine products: emerging therapeutic targets for the treatment of osteoporosis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05879-w

[25] Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study. Archives of Orthopaedic and Trauma Surgery. 2026. DOI: 10.1007/s00402-026-06401-5

[26] Mineralization pattern of vertebral bone material following fragility fracture of the spine. Journal of Orthopaedic Research. 2012. DOI: 10.1002/jor.22026

[27] Structural adaptation and intracortical bone turnover in an ovine model of osteoporosis. Journal of Orthopaedic Research. 2009. DOI: 10.1002/jor.20961

[28] Long-term periprosthetic femoral bone loss after cementless total hip arthroplasty: natural history and response to late osteoporosis treatment. International Orthopaedics. 2026. DOI: 10.1007/s00264-026-07068-8

[29] Low turnover osteoporosis in sheep induced by hypothalamic‐pituitary disconnection. Journal of Orthopaedic Research. 2012. DOI: 10.1002/jor.22066

[30] Incidence of Anti-osteoporosis Diagnosis and Treatment After Distal Radius Fractures. HAND. 2016. DOI: 10.1177/1558944716660555dj

[31] Calcitonin release system in the treatment of experimental osteoporosis. Histomorphometric evaluation. Journal of Orthopaedic Research. 2001. DOI: 10.1016/s0736-0266(01)00074-7

[32] Wristwatch: distal radius fractures as a marker for osteoporosis investigation. Journal of Hand Therapy. 2004. DOI: 10.1197/j.jht.2003.10.030

[33] Osteoporosis is a risk factor for complications and reoperations at 1 and 3 years after arthroscopic rotator cuff repair. JSES International. 2026. DOI: 10.1016/j.jseint.2026.101678

[34] Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. British Journal of Sports Medicine. 2022. DOI: 10.1136/bjsports-2021-104634

[35] Macrophage polarization-related genes with potential causal roles in osteoporosis: a multi-omics Mendelian randomization study. Journal of Orthopaedic Surgery and Research. 2026. DOI: 10.1186/s13018-026-06905-1

[36] Role and mechanism of leptin in improving osteoporosis via the “gut–bone axis”. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09950-3

[37] MiR-137 promotes TLR4/NF-κB pathway activity through targeting KDM4A, inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis. Journal of Orthopaedic Surgery and Research. 2023. DOI: 10.1186/s13018-023-03918-y

[38] Progress in Multiscale Biomechanical Assessment of Cancellous Bone: From Bone Density to Multiscale Mechanical Phenotypes. Injury. 2026. DOI: 10.1016/j.injury.2026.113659

[39] Fracture repair: general aspects and influence of osteoporosis and anti-osteoporosis treatment. Injury. 2016. DOI: 10.1016/s0020-1383(16)30003-1

[40] Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. Journal of Orthopaedic Research. 2010. DOI: 10.1002/jor.21229

[41] Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20505

[42] Hand fragility fractures as a missed opportunity for secondary prevention: A retrospective cohort study and assessment of the Second Metacarpal Cortical Index. Injury. 2026. DOI: 10.1016/j.injury.2026.113261

[43] Wristwatch—distal radial fracture as a marker for osteoporosis investigation:. Journal of Hand Therapy. 2004. DOI: 10.1197/j.jht.2004.04.001

[44] Influence of defective bone marrow osteogenesis on fracture repair in an experimental model of senile osteoporosis. Journal of Orthopaedic Research. 2010. DOI: 10.1002/jor.21041

[45] Postural stability and bone density in postmenopausal women with distal radius fractures. The Journal of Hand Surgery. 1988. DOI: 10.1016/0363-5023(88)90227-4

[46] How do bisphosphonates affect fracture healing?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30015-8

[47] A89 Osteoporosis is not a risk factor for the development of nonunion: a cohort nested case-control study. Injury. 2011. DOI: 10.1016/s0020-1383(11)70106-1

[48] Use of teriparatide in osteoporotic fracture patients. Injury. 2016. DOI: 10.1016/s0020-1383(16)30009-2

[49] Magnetic resonance imaging-based cortical thickness as a predictor of osteoporosis in rotator cuff tears. Shoulder & Elbow. 2026. DOI: 10.1177/17585732261491314

[50] Continuity and volume of bone cement and anti osteoporosis treatment were guarantee of good clinical outcomes for percutaneous vertebroplasty: a multicenter study. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-024-08153-y

[52] SuperLearner approach for predicting imminent risk of fracture in older Chinese patients with newly diagnosed osteoporosis based on their routine blood test markers. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09768-z

[53] Osteoporosis and colles' fractures in the elderly. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand. 1987. DOI: 10.1016/0266-7681(87)90058-1

[55] Ability of osteoclast formation from peripheral monocytes using anti‐fusion regulatory protein‐1/cd98/4f2 monoclonal antibodies in patients with osteoporosis. Journal of Orthopaedic Research. 2000. DOI: 10.1002/jor.1100180215

[56] Diabetes and osteoporosis: a two-sample mendelian randomization study. BMC Musculoskeletal Disorders. 2024. DOI: 10.1186/s12891-024-07430-0

[58] Risk prediction models for postmenopausal osteoporosis: a systematic review and meta-analysis study. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-025-09385-2

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International


Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees


Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.


Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.